At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Medicago Sativa +1 moredrug
Likely dose
Medicago Sativa 1,500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Acute Administration of Medicago Sativa on Glucose Tolerance, Insulin Secretion and Insulin Sensitivity in Normoglycemic, Overweight Adults
In Brief
A Phase 2 clinical trial evaluating Medicago Sativa and Placebo for Glucose Tolerance. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Previous preclinical investigations have found that Medicago sativa promotes the decrease of glucose concentrations. To evaluate the acute effect of Medicago sativa administration on glucose tolerance, insulin secretion, and insulin sensitivity in healthy individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Tolerance
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
Primary CompletionJan 2018
Study CompletionJan 2018
First PostedOct 2018
TodayJul 2026
First PostedOct 22, 2018
Enrollment StartFeb 7, 2017
Primary CompletionJan 11, 2018
Study CompletionJan 30, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.7 years ago
Interventions
Medicago Sativadrug
Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
Placebodietary
Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.